Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Current UConn projects are advancing bioscience

UConn Health is launching a program that uses convalescent plasma from employees who have recovered from COVID-19 to administer to patients suffering from the illness...

| By Kelley Gipson

Biohaven and Cove collaborate against migraine

Biohaven has announced that it is partnering with Cove, a company focused on providing specialized care and access for patients with migraine, particularly through telemedicine....

| By Kelley Gipson

Yale to launch clinical trial re COVID-19 drug

Yale University researchers will begin a clinical trial at Yale-New Haven Hospital to test the effectiveness of a drug called ibudilast (MN-166) for treating acute...

| By Kelley Gipson

2019 annual report shows TIP continues to grow

In 2019, the UConn Technology Incubation Program (TIP) continued to grow, as captured by key metrics, which indicate the overall health and success of its resident...

| By Kelley Gipson

Plan approved for neuroscience center expansion

The New Haven Plan Commission has approved Yale New Haven Health’s plan for a new neuroscience center and expansion at its St. Raphael campus. The...

| By Kelley Gipson

Agreement outlined for 101 College Street project

New Haven has reached a tentative development agreement that would pave the way for a transformative $100 million life-sciences incubator in the heart of downtown...

| By Kelley Gipson

Yale commits to COVID-19 licensing principles

Yale University has signed on to a set of technology licensing principles designed to incentivize and allow for broad and equitable access to university innovations...

| By Kelley Gipson

Tangen partners with BARDA re SARS-CoV-2 test

Tangen Biosciences is developing a rapid diagnostic test for use on the Tangen GeneSparkTM molecular diagnostic system to detect the SARS-CoV-2 virus, with results available...

| By Kelley Gipson

Your input needed re COVID-19 response survey

How is your company addressing the challenges posed by COVID-19? Your feedback is critical and will help direct the response from the Governor and state Department...

| By Kelley Gipson

Alexion to study ULTOMIRIS® therapy re COVID-19

Alexion Pharmaceuticals plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are...